SEOM clinical guideline for the management of malignant melanoma (2017).
SEOM clinical guideline for the management of malignant melanoma (2017).
复制标题
SEOM恶性黑色素瘤管理临床指南(2017年)。
DOI:
10.1007/s12094-017-1768-1
复制
发表时间:
2018-01
期刊:
影响因子:
--
通讯作者:
Algarra SM
中科院分区:
文献类型:
--
作者:
Berrocal A;Arance A;Castellon VE;de la Cruz L;Espinosa E;Cao MG;Larriba JLG;Márquez-Rodas I;Soria A;Algarra SM
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
登录
查看更多内容
DOI:
10.1056/nejmoa1504030
发表时间:
2015-07-02
期刊:
The New England journal of medicine
影响因子:
--
作者:
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者:
Wolchok JD
DOI:
10.1016/s1470-2045(16)30053-5
发表时间:
2016-07
期刊:
The Lancet. Oncology
影响因子:
--
作者:
Goldberg SB;Gettinger SN;Mahajan A;Chiang AC;Herbst RS;Sznol M;Tsiouris AJ;Cohen J;Vortmeyer A;Jilaveanu L;Yu J;Hegde U;Speaker S;Madura M;Ralabate A;Rivera A;Rowen E;Gerrish H;Yao X;Chiang V;Kluger HM
通讯作者:
Kluger HM
影响因子:
158.5
作者:
Robert, Caroline;Schachter, Jacob;Ribas, Antoni
通讯作者:
Ribas, Antoni
影响因子:
51.1
作者:
Burmeister, Bryan H.;Henderson, Michael A.;Thompson, John F.
通讯作者:
Thompson, John F.
影响因子:
51.1
作者:
Dummer, Reinhard;Schadendorf, Dirk;Flaherty, Keith
通讯作者:
Flaherty, Keith